Equity Profile

ADPT

Adaptive Biotechnologies Corporation

Health CareLife Sciences Tools & Services$3.4B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Adaptive Biotechnologies Corporation operates in the health care sector, focusing on life sciences tools and services. The company is known for its innovative approaches to understanding the immune system, which can have significant implications for disease treatment and diagnostics.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's market demand and overall business health.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ADPT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+37.94%

Avg Stock Reaction

-0.91%

Last Quarter Recap

In Q1-2026, Adaptive Biotechnologies reported an EPS of -$0.13, beating estimates by 16.13%. However, the stock fell by nearly 5% the following day, indicating market skepticism despite the earnings surprise.

Management Promises & Guidance

Continued focus on expanding its product offerings.
Commitment to improving operational efficiencies.
Plans to enhance partnerships in the health care sector.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's history of beating EPS estimates. However, the lack of specific guidance may lead to uncertainty about future growth.

Bull Case

If Adaptive Biotechnologies can demonstrate strong revenue growth and continued operational improvements, it could significantly boost investor confidence and stock performance.

Bear Case

Conversely, if the company fails to show meaningful revenue growth or if operational challenges persist, it could lead to further declines in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can the company provide for its new product lines?

Given the company's focus on expanding its offerings, clear revenue figures will be crucial for assessing future growth potential.

How is Adaptive Biotechnologies addressing operational challenges that may impact profitability?

Understanding management's approach to operational efficiency will be key to evaluating the company's path to profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Adaptive Biotechnologies to leverage its recent product innovations to drive significant revenue growth.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

Options pricing suggests a high level of volatility, which may reflect underlying investor confidence not captured in consensus estimates.

Key Risk

If the company reports strong revenue growth from new products, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is keenly watching how the company balances growth with operational efficiency, which will shape investor sentiment.

Bull Confirmed If

Demonstrating revenue growth of over 15% year-over-year would support a bullish outlook.

Bear Confirmed If

A revenue decline or stagnation would confirm bearish sentiments.

Pre-Earnings Positioning

Options Market

Implied Move

±37.62%

Historical Avg

±2.6%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±37.6% while ADPT has averaged ±2.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

53.6%

Calls (1K)P/C Ratio: 0.31Puts (400)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations and raises guidance, history suggests the stock could see an average one-day move of +3.96%.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may react neutrally or slightly down.

Miss

If the company misses expectations, history suggests a potential decline of around -4.97% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of new product lines and their contribution to revenue.
2Any commentary on operational efficiencies and cost management strategies.
3Insights into market demand for Adaptive's offerings.
4Management's outlook on future growth and market opportunities.
5Responses to competitive pressures in the life sciences tools sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's market demand and overall business health.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ADPT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+37.94%

Avg Stock Reaction

-0.91%

Last Quarter Recap

Management Promises & Guidance

Continued focus on expanding its product offerings.
Commitment to improving operational efficiencies.
Plans to enhance partnerships in the health care sector.

Expectations

Wall Street Expectations

Bull Case

If Adaptive Biotechnologies can demonstrate strong revenue growth and continued operational improvements, it could significantly boost investor confidence and stock performance.

Bear Case

Conversely, if the company fails to show meaningful revenue growth or if operational challenges persist, it could lead to further declines in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can the company provide for its new product lines?

Given the company's focus on expanding its offerings, clear revenue figures will be crucial for assessing future growth potential.

How is Adaptive Biotechnologies addressing operational challenges that may impact profitability?

Understanding management's approach to operational efficiency will be key to evaluating the company's path to profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Adaptive Biotechnologies to leverage its recent product innovations to drive significant revenue growth.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

Options pricing suggests a high level of volatility, which may reflect underlying investor confidence not captured in consensus estimates.

Key Risk

If the company reports strong revenue growth from new products, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is keenly watching how the company balances growth with operational efficiency, which will shape investor sentiment.

Bull Confirmed If

Demonstrating revenue growth of over 15% year-over-year would support a bullish outlook.

Bear Confirmed If

A revenue decline or stagnation would confirm bearish sentiments.

Pre-Earnings Positioning

Options Market

Implied Move

±37.62%

Historical Avg

±2.6%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±37.6% while ADPT has averaged ±2.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

53.6%

Calls (1K)P/C Ratio: 0.31Puts (400)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations and raises guidance, history suggests the stock could see an average one-day move of +3.96%.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may react neutrally or slightly down.

Miss

If the company misses expectations, history suggests a potential decline of around -4.97% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of new product lines and their contribution to revenue.
2Any commentary on operational efficiencies and cost management strategies.
3Insights into market demand for Adaptive's offerings.
4Management's outlook on future growth and market opportunities.
5Responses to competitive pressures in the life sciences tools sector.